S3E21 - De-risking drug development using functional human tissues

In this episode of Speaking of Mol Bio, Dr. Andre Ghetti, CEO of AnaBios, offers a deep dive into the world of translational preclinical research. AnaBios is redefining early human insights by using ethically sourced, functional human tissues and cells to generate actionable data before compounds ever enter clinical trials. Ghetti walks us through the company’s approach of offering human-relevant safety and efficacy data, validating drug targets, and supporting everything from small startups to major pharma groups.

We learn how AnaBios engages with clients to customize assays, especially in high-need areas like non-opioid pain therapies, fibrosis, and...